A Phase 4 interventional study of Deucravacitinib and Placebo in Palmoplantar Psoriasis and Genital Psoriasis, sponsored by Bristol-Myers Squibb. Terminated at 31 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.
Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 13th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 4, and was the 18th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in Argentina, Australia, Brazil and 10 more countries
Ages 4–18
Bristol-Myers Squibb
Ages 4–75
By country, each count listing its studies:
deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 10 · Phase 4 8
First in 2016; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 102 across the 26 interventional studies. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 8 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Psoriasis by Bristol-Myers Squibb: 9 open now, 14 under way, 4 of them phase 3. Of 28 finished, 10 (36%) have results posted.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 4, and was the 30th registered.
Bristol-Myers Squibb’s Psoriasis studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing deucravacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 42 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
Key Inclusion Criteria:
Inclusion Criteria for Non-Pustular Palmoplantar Psoriasis
Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a 5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1.
Inclusion Criteria for Genital Psoriasis
Key Exclusion Criteria:
Target Disease Exceptions
Other protocol-defined inclusion/exclusion criteria apply.
Drug: Deucravacitinib
Drug: Deucravacitinib · Drug: Placebo
Specified dose on specified days
Also known as: BMS-986165, SOTYKTU
Specified dose on specified days
Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response
PASI-75 is defined as the percentage of participants who achieve at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) total score. PASI assesses erythema, thickness, and scaling of psoriatic lesions (each rated 0-4), weighted by body region involvement (head, arms, trunk, legs), producing a total score from 0-72, where higher scores indicate more severe disease. Baseline is the Week 0 assessment. PASI-75 responder defined as a 75% improvement from baseline in the PASI score.
Time frame: Week 16
Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response
The Static Physician's Global Assessment (sPGA) OF Genitalia is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The sPGA-G 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.
Time frame: Week 16
Percentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16
The Palmoplantar Physician's Global Assessment (pp-PGA) is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The pp-PGA 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.
Time frame: Week 16
Change From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16
The Genital Psoriasis Symptoms Scale (GPSS) is a participant-administered questionnaire that contains 8 items regarding GenPs symptoms and has a recall period of 24 hours. The items separately address itch, pain, discomfort, stinging, burning, redness, scaling, and cracking on an 11-point scale where 0 represents "no symptom" and 10 represents "worst symptom imaginable". A total score ranging from 0 (no GenPs symptoms) to 80 (worst imaginable GenPs symptoms)
Time frame: Week 16
Number of Participants With Adverse Events
Adverse Events (AEs) are any new or worsening medical occurrences in participants receiving study treatment, regardless of whether they are related to the treatment. AEs include any unfavorable and unintended sign, symptom, or disease temporally associated with treatment. Serious Adverse Events (SAEs) are defined as events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability, are congenital anomalies/birth defects, or are otherwise medically significant.
Time frame: Week 0 through Week 16
Number of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results
Blood samples were collected to assess the laboratory parameters. Laboratory toxicities are graded using NCI CTCAE v3.0. Grade 3 and 4 represent severe and life-threatening abnormalities, respectively.
Time frame: Week 0 through Week 16
Number of Participants With Vital Sign Summaries Per Categories
Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Heart rate was measured in beats/min and DBP and SBP was measured in mmHG.
Time frame: Week 0 through Week 16
| Milestone | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo | Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg |
|---|---|---|---|---|---|---|---|---|
| Started | 30 | 15 | 56 | 29 | 0 | 0 | 0 | 0 |
| Completed | 13 | 8 | 29 | 11 | 0 | 0 | 0 | 0 |
| Not completed | 17 | 7 | 27 | 18 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 15 | 5 | 25 | 13 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo | Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 13 | 8 | 29 | 11 |
| Completed | 0 | 0 | 0 | 0 | 3 | 1 | 5 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 10 | 7 | 24 | 9 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Not reported | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 6 | 6 | 19 | 5 |
PASI-75 is defined as the percentage of participants who achieve at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) total score. PASI assesses erythema, thickness, and scaling of psoriatic lesions (each rated 0-4), weighted by body region involvement (head, arms, trunk, legs), producing a total score from 0-72, where higher scores indicate more severe disease. Baseline is the Week 0 assessment. PASI-75 responder defined as a 75% improvement from baseline in the PASI score.
| percentage of participants | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo Contolled - Palmoplantar Psoriasis - Placebo |
|---|---|---|
| Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response | 31.3 (11.0 to 58.7) | 33.3 (7.5 to 70.1) |
The Static Physician's Global Assessment (sPGA) OF Genitalia is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The sPGA-G 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.
| percentage of participants | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo |
|---|---|---|
| Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response | 48.4 (30.2 to 66.9) | 0 (0 to 24.7) |
The Palmoplantar Physician's Global Assessment (pp-PGA) is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The pp-PGA 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.
| percentage of participants | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo |
|---|---|---|
| Percentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16 | 18.8 (4.0 to 45.6) | 11.1 (0.3 to 48.2) |
The Genital Psoriasis Symptoms Scale (GPSS) is a participant-administered questionnaire that contains 8 items regarding GenPs symptoms and has a recall period of 24 hours. The items separately address itch, pain, discomfort, stinging, burning, redness, scaling, and cracking on an 11-point scale where 0 represents "no symptom" and 10 represents "worst symptom imaginable". A total score ranging from 0 (no GenPs symptoms) to 80 (worst imaginable GenPs symptoms)
| score on a scale | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo |
|---|---|---|
| Change From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16 | -1.9 ± 3.23 | -0.8 ± 2.95 |
Adverse Events (AEs) are any new or worsening medical occurrences in participants receiving study treatment, regardless of whether they are related to the treatment. AEs include any unfavorable and unintended sign, symptom, or disease temporally associated with treatment. Serious Adverse Events (SAEs) are defined as events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability, are congenital anomalies/birth defects, or are otherwise medically significant.
| Participants | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo |
|---|---|---|---|---|
| Adverse Events | 17 | 7 | 31 | 15 |
| Serious Adverse Events | 0 | 0 | 1 | 0 |
Blood samples were collected to assess the laboratory parameters. Laboratory toxicities are graded using NCI CTCAE v3.0. Grade 3 and 4 represent severe and life-threatening abnormalities, respectively.
| Participants | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo |
|---|---|---|---|---|
| Number of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results | 0 | 0 | 2 | 0 |
Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Heart rate was measured in beats/min and DBP and SBP was measured in mmHG.
| Participants | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo |
|---|---|---|---|---|
| HR VALUE > 100 AND CHANGE FROM BASELINE > 30 | 0 | 0 | 0 | 0 |
| HR VALUE < 55 AND CHANGE FROM BASELINE < -15 | 0 | 0 | 0 | 0 |
| SBP VALUE > 140 AND CHANGE FROM BASELINE > 20 | 1 | 0 | 3 | 0 |
| SBP VALUE < 90 AND CHANGE FROM BASELINE < -20 | 0 | 0 | 0 | 0 |
| DBP VALUE > 90 AND CHANGE FROM BASELINE > 10 | 3 | 1 | 6 | 2 |
| DBP VALUE < 55 AND CHANGE FROM BASELINE < -10 | 0 | 0 | 1 | 0 |
Collected over All-cause mortality, serious and non-serious adverse events were collected from Week 0 through Week 52.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | 0/30 (0%) | 0/30 (0%) | 9/30 (30%) |
| Placebo-Controlled Palmoplantar Psoriasis - Placebo | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | 0/56 (0%) | 1/56 (1.8%) | 10/56 (17.9%) |
| Placebo-Controlled Genital Psoriasis - Placebo | 0/29 (0%) | 0/29 (0%) | 10/29 (34.5%) |
| Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | 0/13 (0%) | 1/13 (7.7%) | 2/13 (15.4%) |
| Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg | 0/8 (0%) | 2/8 (25%) | 1/8 (12.5%) |
| Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | 0/29 (0%) | 4/29 (13.8%) | 7/29 (24.1%) |
| Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo | Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg |
|---|---|---|---|---|---|---|---|---|
| Hip fractureInjury, poisoning and procedural complications | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 1/8 | 0/29 | 0/10 |
| Knee arthroplastySurgical and medical procedures | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 1/8 | 0/29 | 0/10 |
| Small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/15 | 0/56 | 0/29 | 1/13 | 0/8 | 0/29 | 0/10 |
| Coronary artery occlusionCardiac disorders | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 0/8 | 1/29 | 0/10 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 0/8 | 1/29 | 0/10 |
| CellulitisInfections and infestations | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 0/8 | 1/29 | 0/10 |
| PneumoniaInfections and infestations | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 0/8 | 1/29 | 0/10 |
| Cardiac failure congestiveCardiac disorders | 0/30 | 0/15 | 1/56 | 0/29 | 0/13 | 0/8 | 0/29 | 0/10 |
| Event | Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Palmoplantar Psoriasis - Placebo | Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD | Placebo-Controlled Genital Psoriasis - Placebo | Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg | Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/30 | 0/15 | 2/56 | 4/29 | 0/13 | 0/8 | 2/29 | 0/10 |
| PneumoniaInfections and infestations | 0/30 | 0/15 | 0/56 | 0/29 | 1/13 | 1/8 | 1/29 | 0/10 |
| Pharyngitis streptococcalInfections and infestations | 0/30 | 0/15 | 1/56 | 0/29 | 1/13 | 0/8 | 0/29 | 1/10 |
| Tinea crurisInfections and infestations | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 0/8 | 0/29 | 1/10 |
| Liver function test increasedInvestigations | 0/30 | 0/15 | 0/56 | 0/29 | 0/13 | 0/8 | 0/29 | 1/10 |
| CholecystitisHepatobiliary disorders | 0/30 | 0/15 | 0/56 | 0/29 | 1/13 | 0/8 | 0/29 | 0/10 |
| InfluenzaInfections and infestations | 2/30 | 1/15 | 0/56 | 1/29 | 1/13 | 0/8 | 1/29 | 0/10 |
| EczemaSkin and subcutaneous tissue disorders | 0/30 | 0/15 | 0/56 | 0/29 | 1/13 | 0/8 | 0/29 | 0/10 |
| PyrexiaGeneral disorders | 0/30 | 0/15 | 0/56 | 2/29 | 0/13 | 0/8 | 0/29 | 0/10 |
| COVID-19Infections and infestations | 0/30 | 0/15 | 0/56 | 2/29 | 0/13 | 0/8 | 0/29 | 0/10 |
| Age, Categorical(Participants) | Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QD | Placebo Contolled - Palmoplantar Psoriasis - Placebo | Placebo Contolled - Genital Psoriasis - BMS-986165 6mg QD | Placebo Contolled - Genital Psoriasis - Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 10 | 52 | 24 | 107 |
| >=65 years | 9 | 5 | 4 | 5 | 23 |
| Sex: Female, Male(Participants) | Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QD | Placebo Contolled - Palmoplantar Psoriasis - Placebo | Placebo Contolled - Genital Psoriasis - BMS-986165 6mg QD | Placebo Contolled - Genital Psoriasis - Placebo | Total |
|---|---|---|---|---|---|
| Female | 17 | 6 | 17 | 9 | 49 |
| Male | 13 | 9 | 39 | 20 | 81 |
| Race/Ethnicity, Customized(Participants) | Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QD | Placebo Contolled - Palmoplantar Psoriasis - Placebo | Placebo Contolled - Genital Psoriasis - BMS-986165 6mg QD | Placebo Contolled - Genital Psoriasis - Placebo | Total |
|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 1 | 0 | 1 |
| ASIAN | 3 | 1 | 1 | 1 | 6 |
| BLACK OR AFRICAN AMERICAN | 0 | 1 | 3 | 1 | 5 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 | 0 | 0 |
| WHITE | 27 | 13 | 49 | 26 | 115 |
| UNKNOWN | 0 | 0 | 2 | 0 | 2 |
| NOT REPORTED | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QD | Placebo Contolled - Palmoplantar Psoriasis - Placebo | Placebo Contolled - Genital Psoriasis - BMS-986165 6mg QD | Placebo Contolled - Genital Psoriasis - Placebo | Total |
|---|---|---|---|---|---|
| HISPANIC OR LATINO | 9 | 3 | 26 | 13 | 51 |
| NOT HISPANIC OR LATINO | 21 | 12 | 29 | 16 | 78 |
| UNKNOWN | 0 | 0 | 0 | 0 | 0 |
| NOT REPORTED | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol-Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.htm
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Oct 2023 to primary completion in Apr 2025, 18 months.
Results were first posted in Apr 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib